Goldman says this biotech could become a global cell therapy leader, has nearly 40% upside
The firm initiated coverage of the stock with a buy rating.
Source link
- This spinal implant tech could restore mobility to Parkinsons patients | TechCrunch
- Photos: Palestinians flee massacre as Israel bombs al-Maghazi refugee camp
